<p>Josh Jennings 給出了買入評級，原因是包括強生在第三季度的財務表現出色。該公司在收入和每股收益方面超出了市場預期，顯示出其創新藥物和醫療科技部門的強勁增長。這一表現突顯了強生有效應對挑戰的能力，例如 Stelara 的專利到期，同時在其他製藥領域仍實現了顯著的銷售增長。</p>
<p>此外，強生還提高了其運營銷售指引，反映出對未來增長前景的信心。該公司預計運營和報告銷售將會增加，這得益於其戰略舉措和旨在長期增長的投資。計劃分拆其骨科部門也被視為進一步擴張的潛在催化劑，這增強了 Jennings 對該股票的積極展望。</p>
<p>根據 TipRanks，Jennings 是一位 3 星分析師，平均回報率為 2.5%，成功率為 47.79%。Jennings 關注醫療保健行業，重點分析 TransMedics Group、波士頓科學和美敦力等股票。</p>
<p>在今天發佈的另一份報告中，瑞銀也維持了該股票的買入評級，目標價為 214.00 美元。</p>

強生

<p>喬什·詹寧斯對強生公司（Johnson & Johnson）發佈了買入評級，指出其第三季度財務表現強勁，超出市場對收入和每股收益的預期。儘管面臨如 Stelara 失去獨佔權等挑戰，公司在創新藥物和醫療科技領域仍顯示出增長。強生已提高其運營銷售指引，表明對未來增長的信心，這得益於包括計劃分拆其骨科部門在內的戰略舉措。瑞銀（UBS）也維持買入評級，目標價為 214 美元</p>

<p>Josh Jennings has given his Buy rating due to a combination of factors, including Johnson &amp; Johnson’s strong financial performance in the third quarter. The company exceeded market expectations with its revenue and earnings per share, showcasing robust growth in both its Innovative Medicine and MedTech segments. This performance highlights JNJ’s ability to effectively manage challenges, such as the loss of exclusivity for Stelara, while still achieving significant sales growth in other pharmaceutical areas.</p>
<div class="lb-trans"><p>Josh Jennings 給出了買入評級，原因是包括強生在第三季度的財務表現出色。該公司在收入和每股收益方面超出了市場預期，顯示出其創新藥物和醫療科技部門的強勁增長。這一表現突顯了強生有效應對挑戰的能力，例如 Stelara 的專利到期，同時在其他製藥領域仍實現了顯著的銷售增長。</p>
</div><p>Additionally, Johnson &amp; Johnson has increased its operational sales guidance, reflecting confidence in its future growth prospects. The company anticipates higher operational and reported sales, supported by its strategic initiatives and investments aimed at long-term growth. The planned separation of its orthopedics division is also seen as a potential catalyst for further expansion, contributing to Jennings’s positive outlook on the stock.</p>
<div class="lb-trans"><p>此外，強生還提高了其運營銷售指引，反映出對未來增長前景的信心。該公司預計運營和報告銷售將會增加，這得益於其戰略舉措和旨在長期增長的投資。計劃分拆其骨科部門也被視為進一步擴張的潛在催化劑，這增強了 Jennings 對該股票的積極展望。</p>
</div><p>According to TipRanks, Jennings is a 3-star analyst with an average return of 2.5% and a 47.79% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic.</p>
<div class="lb-trans"><p>根據 TipRanks，Jennings 是一位 3 星分析師，平均回報率為 2.5%，成功率為 47.79%。Jennings 關注醫療保健行業，重點分析 TransMedics Group、波士頓科學和美敦力等股票。</p>
</div><p>In another report released today, UBS also maintained a Buy rating on the stock with a $214.00 price target.</p>
<div class="lb-trans"><p>在今天發佈的另一份報告中，瑞銀也維持了該股票的買入評級，目標價為 214.00 美元。</p>
</div>

強生第三季度的強勁表現和戰略舉措推動了買入評級